From game-changing trial results to the evolving science behind personalized cancer care, this week’s OncoAlert Round Up dives into the most impactful studies shaking up the oncology landscape. We explore the TALAPRO-2 trial’s final analysis showing that talazoparib plus enzalutamide significantly improves survival in men with HRR-deficient mCRPC—especially those with BRCA1/2 alterations—positioning it as a potential new standard of care. Plus, we unpack new insights into geriatric assessment in oncology, breastfeeding post–HR+ breast cancer (POSITIVE trial), non-clear cell RCC, brain metastases at single-cell resolution, MMR-deficient cancer treatment, microbiome modulation, and more. Whether you're a clinician, researcher, or just passionate about cancer science, this episode delivers everything you need to stay ahead.

Listen now and subscribe for your weekly dose of cutting-edge cancer care.